Psychemedics Corp PMD
We take great care to ensure that the data presented and summarized in this overview for PSYCHEMEDICS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PMD
View all-
22 Nw, LP Seattle, WA276KShares$645,9190.72% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny271KShares$633,8190.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA251KShares$588,0020.0% of portfolio
-
Rbf Capital, LLC San Francisco, CA142KShares$332,6120.02% of portfolio
-
Black Rock Inc. New York, NY71KShares$166,1840.0% of portfolio
-
Wedbush Securities Inc47.9KShares$112,0110.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA47.4KShares$110,8940.0% of portfolio
-
Geode Capital Management, LLC Boston, MA42.7KShares$99,8680.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il21.5KShares$50,3310.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX21.1KShares$49,2800.0% of portfolio
Latest Institutional Activity in PMD
Top Purchases
Top Sells
About PMD
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.
Insider Transactions at PMD
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 17
2023
|
Michael Weisenhoff |
BUY
Grant, award, or other acquisition
|
Direct |
4,000
+50.0%
|
-
|
Aug 17
2023
|
Charles M Doucot Executive Vice President |
SELL
Open market or private sale
|
Direct |
12,700
-35.33%
|
$50,800
$4.66 P/Share
|
Aug 17
2023
|
Darius G Nevin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+37.84%
|
-
|
Aug 17
2023
|
Peter Kamin Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+5.58%
|
-
|
Aug 17
2023
|
Robyn C Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+26.42%
|
-
|
Aug 17
2023
|
Andrew Reynolds Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,000
+33.33%
|
-
|
May 22
2023
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,500
-0.6%
|
$6,000
$4.93 P/Share
|
May 22
2023
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
825
-2.24%
|
$3,300
$4.93 P/Share
|
May 22
2023
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
375
-1.02%
|
$1,500
$4.93 P/Share
|
May 15
2023
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,725
-0.69%
|
$6,900
$4.87 P/Share
|
May 15
2023
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
337
-0.91%
|
$1,348
$4.87 P/Share
|
May 15
2023
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
900
-2.39%
|
$3,600
$4.87 P/Share
|
Dec 16
2022
|
Michael I Schaffer VP of Laboratory Operations |
BUY
Open market or private purchase
|
Direct |
100
+0.27%
|
$400
$4.95 P/Share
|
Nov 11
2022
|
Charles M Doucot Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
1,350
-3.46%
|
$8,100
$6.18 P/Share
|
Nov 11
2022
|
Raymond C Kubacki Jr Chairman, CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,625
-1.04%
|
$15,750
$6.18 P/Share
|
Nov 11
2022
|
Michael I Schaffer VP of Laboratory Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
525
-1.4%
|
$3,150
$6.18 P/Share
|
Aug 12
2022
|
Darius G Nevin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+50.0%
|
-
|
Aug 12
2022
|
Peter Kamin Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,000
+3.88%
|
-
|
May 20
2022
|
Raymond C Kubacki Jr Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+7.34%
|
-
|
May 20
2022
|
Michael I Schaffer VP of Laboratory Operations |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+11.73%
|
-
|